Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia

Bone Marrow Transplantation volume 58, pages 826–828 (2023)Cite this article

Subjects

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–41. https://doi.org/10.1182/blood.2020009984.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, et al. The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transplant. 2020;26:1137–43. https://doi.org/10.1016/j.bbmt.2020.02.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020;26:472–9. https://doi.org/10.1016/j.bbmt.2019.10.017.

    Article  CAS  PubMed  Google Scholar 

  4. DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016:466–71.e1. https://doi.org/10.1016/j.clml.2016.04.017.

  5. Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, et al. Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014;99:1492–8. https://doi.org/10.3324/haematol.2013.100198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Petrungaro A, Gentile M, Mazzone C, Greco R, Uccello G, Recchia AG, et al. Ponatinib-induced graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia without the T315I mutation relapsing after allogeneic transplant. Chemotherapy. 2017;62:353–6. https://doi.org/10.1159/000477714.

    Article  CAS  PubMed  Google Scholar 

  7. Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, et al. Rome Transplant Network. Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant. Chemotherapy. 2017;62:58–61. https://doi.org/10.1159/000448750.

    Article  CAS  PubMed  Google Scholar 

  8. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–3. https://doi.org/10.1182/blood-2006-04-019836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96:1113–20. https://doi.org/10.3324/haematol.2011.040261.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget. 2018;9:13423–37. https://doi.org/10.18632/oncotarget.24393.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26. https://doi.org/10.1056/NEJMoa1902328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

JFA and DM are grateful for the support of the Imperial College National Institute of Health Research (NIHR) Biomedical Research Centre and Blood Cancer UK Vaccine Research Collaborative, a partnership between Blood Cancer UK, Myeloma UK, Anthony Nolan and the British Society of Haematology (Grant 21011).

Author information

Authors and Affiliations

  1. Centre for Haematology, Imperial College London, London, UK

    Fiona Fernando, Andrew J. Innes, Simone Claudiani, Angharad Pryce, Jane F. Apperley & Dragana Milojkovic

  2. Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK

    Fiona Fernando, Andrew J. Innes, Simone Claudiani, Angharad Pryce, Jane F. Apperley & Dragana Milojkovic

  3. North West London Pathology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

    Chloe Hayden

  4. Centre for Clinical Haematology, Nottingham University Hospital NHS Trust, Nottingham, UK

    Jenny Byrne

  5. Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK

    Paolo Gallipoli

  6. Paul O’Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK

    Mhairi Copland

Authors
  1. Fiona Fernando
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Innes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simone Claudiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angharad Pryce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chloe Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jenny Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paolo Gallipoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mhairi Copland
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jane F. Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dragana Milojkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DM, SC, JFA, AJI and FF were involved in the clinical care of patients included in the study. FF and DM wrote the manuscript. All authors reviewed and edited the manuscript and figures. All authors approved the final manuscript version.

Corresponding author

Correspondence to Fiona Fernando.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernando, F., Innes, A.J., Claudiani, S. et al. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Bone Marrow Transplant 58, 826–828 (2023). https://doi.org/10.1038/s41409-023-01975-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-01975-9

Search

Advanced search

Quick links